ISR's Hepatitis C Market Analysis Shows a Deep Pipeline, Uncovers Lack of Internet Search Visibility for Current Therapies

Industry Standard Research (ISR) today announced the availability of their latest report, “Hepatitis C: Social Media, Search, and Market Analysis,” providing a product and pipeline analysis of the Hepatitis C market, as well as a never before seen in-depth social media and search analysis detailing how individuals discuss and search for Hepatitis C information, where they go to find it, and how their search progresses.

“Hepatitis C is the leading cause of liver cancer in the US and is believed to affect 170–200 million individuals worldwide” explained Andrew Schafer, President of ISR. “Given the ups and downs in recent weeks, expectations for Hep C treatments remain high. This report gives both clinical development and brand managers information they need to meet these expectations.”

ISR’s report includes a social media and search analysis of Hepatitis C.

“The analysis of natural search engine ranking pages (SERPs) of commonly searched keyword phrases in the Hep C search continuum uncovered a gap in what information users were searching for and what they expected to receive,” Schafer explained. “With few products available, this gap represents a tremendous opportunity for a drug maker to assert themselves as the information resource for Hepatitis C.”
                                                                                                  
ISR’s report also provides a disease overview; profile of current products and companies in the market; addressable market; and in-depth analysis of clinical trial activity, including 707 trials that are on-going or have been completed in the past two years to provide further understanding of Hepatitis C clinical development environment and trends. Analysis includes the number of trials by phase, the average enrollment, the average length of the studies, the sponsor type, and the types of studies being run.

The report profiles the products and pipelines of 10 companies, including Achillion, BMS, Boehringer Ingelheim, Genentech/Roche, Gilead Sciences, Idenix, Johnson & Johnson, Merck, Novartis, and Vertex.